Clinical Pediatric Dermatology Open Access

  • ISSN: 2472-0143
  • Journal h-index: 3
  • Journal CiteScore: 0.24
  • Journal Impact Factor: 0.11
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Study of the molecular and functional effects of wound dressings on human dermal fibroblasts

Joint Event on 5th International Conference on Advances in Skin, Wound Care and Tissue Science & 14th International Conference on Clinical Dermatology
October 15-16, 2018 Rome, Italy

Michel Laurence, Armstrong Florence, Ly Ka So Sophie, Da Silva Cindy, Proust Richard, Samardzic Marin, Bagot Martine and Bensussan A

Hospital Saint-Louis, France Les Laboratoires Brothier, France

Scientific Tracks Abstracts: Clin Pediatr Dermatol

Abstract:

The process of cutaneous healing/repair is characterized by three major phases, closely related: Coagulation (A) and inflammation (B) during the first hours involving immune cells of the innate response, followed over time by a regeneration phase and a remodeling/maturation phase (C) mainly conducted by dermal fibroblasts. To promote tissue repair, there is a multitude of dressings targeting the different phases of healing including calcium alginates and high absorbency fibers. The aim of the present study was to determine the effects of these wound dressings subtypes on human dermal fibroblasts, knowing that some of them do act on the coagulation and hemostasis phase as well as on the wound debridement Primary cultures of dermal fibroblasts were established from human surgical normal skin residues (n=6 to 12) and were studied for their molecular and functional responses to conditioned media from three wound dressings: Calcium alginate Algosteril®, Biatain® Alginate and UrgoClean®. The results showed that Algosteril® dressing among the 3 dressings significantly promoted the cell migration and consequently the closure of the dermal wounds as demonstrated by scratching experiments. No alteration of the viability of dermal fibroblasts was depicted with Algosteril® and Biatain® Alginate, whereas UrgoClean® did. Concerning gene macro-arrays induced in TGFβ-activated fibroblasts, Algosteril® significantly increased the synthesis of main collagens, extracellular matrix-remodeling enzymes, cytokines promoting fibroblast migration and proliferation, as well as allowing the recruitment of immune cells and thus promoting the development of an innate response that ensures the debridement of the wound. Biatain® Alginate was less efficient than Algosteril® Stimulation of pro-inflammatory cytokine production was also significantly increased with Algosteril® whereas it was not with other studied dressings. Altogether, our results about these different parameters pointed out that Algosteril® among other dressings will facilitate the repair of the tissue matrix and prepare an effective healing phase.

Biography :

Laurence MICHEL is a team research group manager at Inserm Unit U976, Paris Saint-Louis Hospital. She works in the Skin Research Center conducted by Professor Martine BAGOT, head of the Saint-Louis Dermatology Department and director Armand BENSUSSAN, U976 director. During her carrier, she has been carried out clinical research in collaboration with the hospital Clinic Investigative Center, studying mechanisms of allergic and inflammatory cutaneous diseases in patients and providing her expertise in pharmacology for in vivo testing of new therapies in collaboration with pharmaceutics/cosmetics laboratories. She also worked as a fundamental researcher studying the mechanism of signalling pathways involved in inflammatory skin disorders and cutaneous cell resistance to treatment. Focus has been done on skin aging, dermal fibrosis, xerosis (dry skin), hair greying, depigmentation and hair loss, besides cutaneous pathologies (atopy, cutaneous T cell lymphoma). External expert in national and international academic institutions. Author of 68 articles and 3 patents.

E-mail: laurence.michel@inserm.fr